TY - JOUR
T1 - Prognostic significance of decreased expression of six large common fragile site genes in oropharyngeal squamous cell carcinomas
AU - Gao, Ge
AU - Kasperbauer, Jan L.
AU - Tombers, Nicole M.
AU - Cornell, Melissa D.
AU - Smith, David I.
N1 - Funding Information:
We want to thank Ann Oberg for her kind suggestions in statistical analysis. This work is supported by the Experimental Pathology Development Fund from the Department of Laboratory Medicine and Pathology at Mayo Clinic .
Publisher Copyright:
© 2014 Neoplasia Press, Inc.
PY - 2014
Y1 - 2014
N2 - Common fragile sites (CFSs) are large regions with profound genomic instability that often span extremely large genes a number of which have been found to be important tumor suppressors. RNA sequencing previously revealed that there was a group of six large CFS genes which frequently had decreased expression in oropharyngeal squamous cell carcinomas (OPSCCs) and real-time reverse transcriptase polymerase chain reaction experiments validated that these six large CFS genes (PARK2, DLG2, NBEA, CTNNA3, DMD, and FHIT) had decreased expression in most of the tumor samples. In this study, we investigated whether the decreased expression of these genes has any clinical significance in OPSCCs. We analyzed the six CFS large genes in 45 OPSCC patients and found that 27 (60%) of the OPSCC tumors had decreased expression of these six genes. When we correlated the expression of these six genes to each patient’s clinical records, for 11 patients who had tumor recurrence, 10 of them had decreased expression of almost all 6 genes. When we divided the patients into two groups, one group with decreased expression of the six genes and the other group with either slight changes or increased expression of the six genes, we found that there is significant difference in the incidence of tumor recurrence between these two groups by Kaplan-Meier plot analysis (P <.05). Our results demonstrated that those OPSCC tumors with decreased expression of this select group of six large CFS genes were much more likely to be associated with tumor recurrence and these genes are potential prognostic markers for predicting tumor recurrence in OPSCC.
AB - Common fragile sites (CFSs) are large regions with profound genomic instability that often span extremely large genes a number of which have been found to be important tumor suppressors. RNA sequencing previously revealed that there was a group of six large CFS genes which frequently had decreased expression in oropharyngeal squamous cell carcinomas (OPSCCs) and real-time reverse transcriptase polymerase chain reaction experiments validated that these six large CFS genes (PARK2, DLG2, NBEA, CTNNA3, DMD, and FHIT) had decreased expression in most of the tumor samples. In this study, we investigated whether the decreased expression of these genes has any clinical significance in OPSCCs. We analyzed the six CFS large genes in 45 OPSCC patients and found that 27 (60%) of the OPSCC tumors had decreased expression of these six genes. When we correlated the expression of these six genes to each patient’s clinical records, for 11 patients who had tumor recurrence, 10 of them had decreased expression of almost all 6 genes. When we divided the patients into two groups, one group with decreased expression of the six genes and the other group with either slight changes or increased expression of the six genes, we found that there is significant difference in the incidence of tumor recurrence between these two groups by Kaplan-Meier plot analysis (P <.05). Our results demonstrated that those OPSCC tumors with decreased expression of this select group of six large CFS genes were much more likely to be associated with tumor recurrence and these genes are potential prognostic markers for predicting tumor recurrence in OPSCC.
UR - http://www.scopus.com/inward/record.url?scp=84915811767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84915811767&partnerID=8YFLogxK
U2 - 10.1016/j.tranon.2014.09.009
DO - 10.1016/j.tranon.2014.09.009
M3 - Article
AN - SCOPUS:84915811767
SN - 1936-5233
VL - 7
SP - 726
EP - 731
JO - Translational Oncology
JF - Translational Oncology
IS - 6
ER -